Retrospective analysis of long-term hemorheologic effects of pentoxifylline in diabetic patients with angiopathic complications

Acta Diabetologica

Volumn 34, Issue 2, 1997, Pages 67-74

  Solerte, S B ^a   Fioravanti, M ^a   Cerutti, N ^a   Severgnini, S ^a   Locatelli, M ^a   Pezza, N ^a   Rondanelli, M ^a   Trecate, L ^a   Balza, G ^a   Ferrari, E ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Albuminuria; Angiopathy; Fibrinogen; Hemorheology; Pentoxifylline

Indexed keywords

ALBUMIN; FIBRINOGEN; PENTOXIFYLLINE;

ADULT; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE; BLOOD RHEOLOGY; BLOOD VISCOSITY; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; ERYTHROCYTE AGGREGATION; ERYTHROCYTE FILTERABILITY; FEMALE; HEMATOCRIT; HUMAN; MALE; PLASMA VISCOSITY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RETROSPECTIVE STUDY; URINARY EXCRETION; VASCULAR DISEASE;

ADULT; AGED; ALBUMINURIA; BLOOD PRESSURE; BLOOD VISCOSITY; DIABETIC ANGIOPATHIES; FEMALE; FIBRINOGEN; HUMANS; MALE; PENTOXIFYLLINE; RETROSPECTIVE STUDIES; RHEOLOGY; VASODILATOR AGENTS;

EID: 9844250198     PISSN: 09405429     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005920050069     Document Type: Article

References (48)

1. McMillan DE, Hemorheologic therapy to control diabetic vascular disease. Clin Hemorheol 12:787-796, 1992
2. Campbell RK, Clinical update on pentoxifylline therapy for diabetes-induced peripheral vascular disease. Ann Pharmacother 27:1099-1105, 1993
3. Masowetzkij A, Stoilov G, Kukashina LD, Tirkina TV, Titova SL, The use of pentoxifylline in diabetes mellitus. Pharmatherapeutica 2 [Suppl 1]:105-108, 1978
4. Smud R, Sermukslis B, Kartin D, Changes in blood viscosity induced by pentoxifylline. Pharmatherapeutica 1:229-233, 1976
5. Ehrly AM, Improvement of the flow properties of blood. A new therapeutic approach in occlusive arterial disease. Angiology 27:188-196, 1976
6. Angelkort B, Maurin N, Boateg K, Influence of pentoxifylline on erythrocyte deformability in peripheral occlusive arterial disease. Curr Med Res Opin 6:255-258, 1979
7. Di Perri T, Guerrini M, Placebo controlled double blind study with pentoxifylline of walking performance in patients with intermittent claudication. Angiology 34:40-45, 1983
8. Aviado DM, Dettelbach HR, Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication. Angiology 35:407-417, 1984
9. Muller R, Hemorheology and peripheral vascular diseases: a new therapeutic approach. J Med 12:209-236, 1981
10. Solerte SB, Ferrari E, Diabetic retinal vascular complications and erythrocyte filterability: results of a 2-year follow-up study with pentoxifylline. Pharmatherapeutica 4:341-350, 1985
11. Solerte SB, Fioravanti M, Bozzetti A, Schifino N, Patti AL, Fedele P, Viola C, Ferrari E, Pentoxifylline, albumin excretion rate and proteinuria in type 1 and type 2 diabetic patients with microproteinuria. Results of a short-term randomized study. Acta Diabetol Lat 23:171-177, 1986
12. Solerte SB, Fioravanti M, Patti AL, Schifino N, Zanoletti MG, Inglese V, Ferrari E, Pentoxifylline, total urinary protein excretion and arterial blood pressure in long-term insulin-dependent diabetic patients with overt nephropathy. Acta Diabetol Lat 24:229-239, 1987
13. Ferrari E, Fioravanti M, Patti AL, Viola C, Solerte SB, Effects of a long-term treatment (4 years) with pentoxifylline on hemorheological changes and vascular complications in diabetic patients. Pharmatherapeutica 5:26-39, 1987
14. Solerte SB, Fioravanti M, Berard P, Rondanelli M, Perego M, Ferrari E, Therapeutic strategies in the prevention of diabetic angiopathy. Ten-years (1982-1992) retrospective study of hemorheologic therapy with pentoxifylline. Clin Hemorheol 13:381. 1993
15. Mogensen CE, Christensen CK, Vittinghus E, The stage in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes [Suppl 2] 32:64-78, 1983
16. Viberti GC, Keen H, The pattern of proteinuria in diabetes mellitus. Relevance to pathogenesis and prevention of diabetic nephropathy. Diabetes 33:686-692, 1984
17. Bradford MM, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein dye binding. Anal Biochem 72:248-254, 1976
18. International Committee for Standardization in Hematology, Guidelines for measurement of blood viscosity and erythrocyte deformability. Clin Hemorheol 6:439-453, 1986
19. Cordaro C, Caradente O, Esperienze pratiche sulla metodica di filtrazione eritrocitaria. Ric Clin Lab 10:1-14, 1980
20. Reid H, Barnes AJ, Lock PI, Dormandy JA, A simple method for measuring erythrocyte deformability. J Clin Pathol 29:855-858, 1976
21. Solerte SB, Locatelli M, Pezza N, Severgnini S, Schifino N, Martinoli C, Furini A, Ferrari E, Fioravanti M, Haemorheology and cerebrovascular disease in aging. Retrospective analysis of associated risk factors. Facts Res Geront 7-22, 1996
22. McMillan DE, Plasma protein changes, blood viscosity, and diabetic micro-angiopathy. Diabetes [Suppl 2] 25:858-864, 1976
23. Barnes AJ, Locke P, Scudder PR, Dormandy TL, Dormandy JA, Slack J, Is hyperviscosity a treatable component of diabetic microcirculatory disease? Lancet 2:789-791, 1977
24. Lowe GDO, Lowe JM, Drummond MM, Reith S, Belch JJF, Kesson CM, Wylie A, Foulds WS, Forbes CD, MacCuish AC, Manderson WG, Blood viscosity in young male diabetics with and without retinopathy. Diabetologia 18:359-363, 1980
25. McMillan DE, Physical factors important in the development of atherosclerosis in diabetes. Diabetes [Suppl 2] 30:97-104, 1981
26. Simpson LO, A hypothesis proposing increased blood viscosity as a cause of proteinuria and increased vascular permeability. Nephron 31:89-93, 1982
27. McMillan DE, The effect of diabetes on blood flow properties. Diabetes [Suppl 2] 30:56-63, 1983
28. Caimi G, Blood viscosity and erythrocy te filterability: their evaluation in diabetes mellitus Horm Metab Res 15:467-470, 1983
29. Solerte SB, Piovella F, Viola C, Carnevale Schianca GP, Gamba G, Fioravanti M, Ferrari E, Plasma fibronectin, Von Willebrand factor antigen and blood rheology. Association with diabetic microvascular disease. Acta Diabetol Lat 22:239-246, 1985
30. Ernst E, Fibrinogen, a cardiovascular risk factor. Clin Hemorheol 12:805-816, 1992
31. Schmid-Schonbein H, Microrheology of erythrocytes, blood viscosity and the distribution of blood flow in the microcirculation. Int Rev Physiol 9:1-62, 1976
32. Dintenfass L, Viscosity factors in hypertensive and cardiovascular disease. Cardiovasc Med 2:337-357, 1977
33. Rodkiewcz CM, Localization of early atherosclerotic lesions in the aortic arch in the light of fluid mechanismics. J Biomech 8:149-156, 1975
34. Fry DL, Acute vascular endothelial changes associated with increased blood velocity gradients. Circ Res 22:165-197, 1968
35. Dormandy JA, Hemorheological aspects of thrombosis. Br J Hematol 45:519-522, 1980
36. Lowe GDD, Forbes CD, Blood rheology and thrombosis. Clin Hematol 10:343-367, 1981
37. Müller R, Lehrach F, Haemorheological role of platelet aggregation and hypercoagulability in microcirculation: therapeutical approach with pentoxifylline. Pharmatherapeutica 2:372-379, 1980
38. Chien S, Blood rheology in hypertension and cardiovascular disease. Cardiovasc Med 2:356-360, 1977
39. Dintenfass L, Malfunction of viscosity receptors (viscoreceptors) as the cause of hypertension. Am Heart J 92:260-263, 1976
40. Scholz PM, Karis JK, Gump FE, Kinney JM, Chien S, Correlation of blood rheology with vascular resistance in critically ill patients. J Appl Physiol 39:1008-1011, 1975
41. Letcher RL, Chien S, Pickering TG, Sealey JE, Laragh JH, Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects. Am J Med 70:1195-1202, 1981
42. Solerte SB, Ferrari E, Arterial hypertension and haemorheological abnormalities in diabetes mellitus. Clin Haemorheol 5:699, 1985
43. Hoare EM, Barnes AJ, Dormandy JA, Abnormal blood viscosity in diabetes mellitus and retinopathy. Biorheology 13:21-25, 1976
44. Solerte SB, Carnevale Schianca GP, Viola C, Adamo S, Cozzi A, Crippa A, Ferrari E, Pathogenetic mechanism of haemorheological factors in development and progression of diabetic nephropathy Clin Hemorheol 3:327, 1983
45. Solerte SB, Fioravanti M, Hemodynamic alterations in long-term insulin-dependent diabetic patients with overt nephropathy: role of blood hyperviscosity and plasma protein changes. Clin Nephrol 28:138-143, 1987
46. Mogensen CE, Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356-360, 1984
47. Mattock MB, Morrish NJ, Viberti GC, Keen H, Fitzgerald AP, Jackson G, Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 41:736-741, 1992
48. Yudkin JS, Forrest R, Jackson CA, Microalbuminuria predictor of vascular disease in non-diabetic subjects. Lancet 1:530-533, 1988